Laboratory variables and stratification of metastatic colorectal cancer patients: Recommendations for therapeutic trials and for clinical practice guidelines

Clinica Chimica Acta

Volumn 345, Issue 1-2, 2004, Pages 1-15

  Watine, Joseph ^a   Friedberg, Bruno ^a  

^a HÔPITAL DU BOCAGE   (France)

Author keywords

Metastatic colorectal cancer; Practice guideline; Staging; Stratification; Survival; Systematic review; Therapeutic trial

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PROTHROMBIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CLINICAL PRACTICE; CLINICAL RESEARCH; COLORECTAL CARCINOMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; KINETICS; LABORATORY TEST; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER FUNCTION; LIVER FUNCTION TEST; MEASUREMENT; MEDICAL LITERATURE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PUBLISHING; REVIEW; STATISTICAL ANALYSIS; STRATIFICATION; TASK PERFORMANCE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DIAGNOSIS; GUIDELINES; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; NEOPLASM METASTASIS; RESEARCH DESIGN;

EID: 2942541207     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2004.02.017     Document Type: Review

References (74)

1. Bismuth H., Adam R., Levi F., Farabos C., Waechter F., Castaing D., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg. 224:1996;509-520. [discussion 520-2]
2. Kohne C.H., Cunningham D., Di C.F., Glimelius B., Blijham G., Aranda E., et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 13:2002;308-317
3. Fielding L.P., Fenoglio-Preiser C.M., Freedman L.S. The future of prognostic factors in outcome prediction for patients with cancer. Cancer. 70:1992;2367-2377
4. Altman D.G., Schulz K.F., Moher D., Egger M., Davidoff F., Elbourne D., et al. The revised CONSORT statement for reporting randomised trials: explanation and elaboration. Ann. Intern. Med. 134:2001;663-694
5. Friedberg B., Watine J., Miédougé M. Unresected colorectal liver metastases: prognostic value of laboratory variables. Gastroenté rol. Clin. Biol. 25:2001;962-966. [in French; full text available in English at: http://www.e2med.com/gcb]
6. Horvath A.R., Pewsner D. Systematic reviews in laboratory medicine: principles, processes and practical considerations. Clin. Chim. Acta. 342:2004;23-39
7. Oosterhuis W.P., Niessen R.W.L.M., Bossuyt P.M.M. The science of systematic reviewing studies of diagnostic tests. Clin. Chem. Lab. Med. 38:2000;577-588
8. Sandberg S., Oosterhuis W., Freedman D., Kawai T. Systematic reviewing in laboratory medicine. Position paper from the IFCC committee on systematic reviewing in laboratory medicine. J. Int. Fed. Clin. Chem. 9:1997;154-155
9. Watine J., Miédougé M., Friedberg B. Carcinoembryonic antigen as an independent prognostic factor of recurrence and survival in patients resected for colorectal liver metastases: a systematic review. Dis. Colon Rectum. 44:2001;1791-1799. [Full text available free of charge at: http://www.discolrect.com]
10. Cox D.R. Regression models and life-tables. [with discussion] J. R. Stat. Soc. B34:1972;187-202
11. Bedikian A.Y., Chen T.T., Malahy M., Patt Y.Z., Bodey G.P. Prognostic factors influencing survival in patients with advanced colorectal cancer: hepatic artery infusion versus systemic intravenous chemotherapy for liver metastases. J. Clin. Oncol. 2:1984;174-180
12. Cunningham D., Pyrhonen S., James R.D., Punt C.J., Hickish T.F., Heikkila R., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 352:1998;1413-1418
13. Edler L., Heim M.E., Quintero C., Brummer T., Queisser W. Prognostic factors of advanced colorectal cancer patients. Eur. J. Cancer Clin. Oncol. 22:1986;1231-1237
14. Elias D., Ducreux M., Rougier P., Commandella M.G., Deraco M., Ramirez L., et al. Chimiothérapie intra-artérielle hépatique. Expérience de 200 cas. Gastroentérol. Clin. Biol. 18:1994;975-982
15. Fortner J.G., Silva J.S., Cox E.B., Goldbey R.B., Gallowitz H., MacLean B.J. Multivariate analysis of a personal series of 247 patients with liver metastases from colorectal cancer: II. Treatment by intrahepatic chemotherapy. Ann. Surg. 199:1984;317-324
16. Fountzilas G., Gossios K., Zisiadis A., Svarna E., Skarlos D., Pavlidis N. Prognostic variables in patients with advanced colorectal cancer treated with fluorouracil and leucovirin-based chemotherapy. Med. Pediatr. Oncol. 26:1996;305-317
17. Kemeny N., Niedzwiecki D., Shurgot B., Oderman P. Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement. Cancer. 63:1989;742-747
18. Lahr C.J., Soong S.J., Cloud G.C., Smith J.W., Urist M.M., Balch C.M. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J. Clin. Oncol. 1:1983;720-726
19. Mackean M.J., Cassidy J., Jodrell D.I., Paul J., Reed N.S., Canney P.A., et al. Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. Br. J. Cancer. 77:1998;1480-1486
20. Rougier P., Milan C., Lazorthes F., Fourtanier G., Partensky C., Baumel H., et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br. J. Surg. 82:1995;1397-1400
21. Rougier P., Van Cutsem E., Bajetta E., Niederle N., Possinger K., Labianca R., et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 352:1998;1407-1412
22. Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N. Engl. J. Med. 343:2000;905-914
23. Stangl R., Altendorf-Hofmann A., Charnley R.M., Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 343:1994;1405-1410
24. Steinberg J., Erlichman C., Gadalla T., Fine S., Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur. J. Cancer. 28A:1992;1817-1820
25. ACBI (Association of Clinical Biochemists in Ireland) Guidelines for the use of tumour markers. Second ed. 2000 September;. [Downloadable at: http://www.acbi.ie]
26. Compton C., Fenoglio-Preiser C.M., Pettigrew N., Fielding L.P. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer. 88:2000;1739-1757
27. Agence Nationale pour l'Accréditation et l'Evaluation en Santé (ANAES) Recommandations et références médicales. Marqueurs sériques dans les cancers du sein et les cancers colorectaux. 1997;. [Downloadable at: http://www.anaes.fr/]
28. Bast R.C. Jr., Ravdin P., Hayes D.F., Bates S., Fritsche H. Jr., Jessup J.M., et al. American society of clinical oncology tumor markers expert panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol. 19:2001;1865-1878
29. Compton C.C., Fielding L.P., Burgart L.J., Conley B., Cooper H.S., Hamilton S.R., et al. Prognostic factors in colorectal cancer. College of American Pathologists consensus statement 1999. Arch. Pathol. Lab. Med. 124:2000;979-994
30. Duffy M.J., van Dalen A., Haglund C., Hansson L., Klapdor R., Lamerz R., et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur. J. Cancer. 39:2003;718-727
31. ESMO (European Society for Medical Oncology) ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann. Oncol. 12:2001;1053-1054. [Downloadable at: http://www.esmo.org/reference/ CC_adj.htm]
32. ESMO (European Society for Medical Oncology) ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer. Ann. Oncol. 12:2001;1055. [Downloadable at: http://www.esmo.org/ reference/CRCadv.htm]
33. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Standards, options and recommendations for tumor markers in colorectal cancer [Downloadable at: http://www.fnclcc.fr/].
34. SIGN (Scottish Intercollegiate Guidelines Network) Management of colorectal cancer, a national clinical guideline. 2003 (March);. [Downloadable at: http://www.sign.ac.uk/]
35. Société Nationale Française de Gastroenté rologie (SNFGE) Conférence de consensus 1998. Prévention, dépistage et prise en charge des cancers du côlon. Gastroentérol. Clin. Biol. 22(Suppl. 3):1998;S1-S295
36. Bruinvels D.J., Stiggelbout A.M., Kievit J., van Houwelingen H.C., Habbema J.D., van de Velde C.J. Follow-up of patients with colorectal cancer. A meta-analysis. Ann. Surg. 219:1994;174-182
37. Figueredo A., Rumble R.B., Maroun J., Earle C.C., Cummings B., McLeod R., et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 3:2003;26. [Full text available free of charge at: http://www.biomedcentral.com/1471-2407/3/26]
38. Renehan A.G., Egger M., Saunders M.P., O'Dwyer S.T. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ. 324:2002;813. [full text available free of charge at: http:/www.bmj.com]
39. Rosen M., Chan L., Beart R.W. Jr., Vukasin P., Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis. Colon Rectum. 41:1998;1116-1126. [Full text available free of charge at: http://www.discolrect.com]
40. Watine J. Laboratory variables to stratify metastatic colorectal cancer patients. Ann. Oncol. 14:2003;1450-1451
41. Köhne C.H., Hecker H. Reply to Letter to the Editor "Laboratory variables to stratify metastatic colorectal cancer patients", by J. Watine (Ann. Oncol. 2003; 14: 1450-1551). Ann. Oncol. 14:2003;1450-1451
42. Watine J. Laboratory variables as additional staging parameters in patients with small-cell lung carcinoma. A systematic review. Clin. Chem. Lab. Med. 37:1999;931-938
43. Watine J. Prognostic score for Hodgkin's disease. N. Engl. J. Med. 340:1999;1289
44. Watine J. Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review. Scand. J. Clin. Lab. Invest. 60:2000;259-274
45. Watine J. Baseline staging tests in primary breast cancer. CMAJ. 165:2001;1301. [full text available free of charge at: http://www.cmaj.ca/cgi/ content/full/165/10/1301]
46. Haeckel R., Wosniok W., Puentmann I. Discordance rate, a new concept for combining diagnostic decisions with analytical performance characteristics: 1. Application in method or sample system comparisons and in defining decision limits. Clin. Chem. Lab. Med. 41:2003;347-355
47. Leger F., Seronie-Vivien S., Makdessi J., Lochon I., Delord J.P., Sarda C., et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur. J. Cancer. 38:2002;52-56
48. Waugh J., Bell S.C., Kilby M., Lambert P., Shennan A., Halligan A. Effect of concentration and biochemical assay on the accuracy of urine dipsticks in hypertensive pregnancies. Hypertens Pregnancy. 20:2001;205-217
49. Von Eyben F.E., Petersen P.H., Blaabjerg O., Madsen E.L. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin. Chem. Lab. Med. 37:1999;553-561
50. Hsi E.D., Kopecky K.J., Appelbaum F.R., Boldt D., Frey T., Loftus M., et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br. J. Haematol. 120:2003;1017-1025
51. Mainou-Fowler T., Dignum H., Taylor P.R., Dickinson A.M., Saunders P.W., Proctor S.J., et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 118:2002;755-761
52. Watine J., Miédougé M. Pre-analytical variation of laboratory variables. Clin. Chem. Lab. Med. 38:2000;263
53. Young D.S. Conveying the importance of the preanalytical phase. Clin. Chem. Lab. Med. 41:2003;884-887
54. Mauriat F. Systèmes de santé et biologie en France et en Europe. Spectra Biol. 19:2000;21-32
55. Kemeny N., Braun D.W. Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood count. Am. J. Med. 74:1983;786-794
56. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. STARD group. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin. Chem. Lab. Med. 41:2003;68-73
57. Hacini J., Watine J. Yet another example of lack of biological expertise in certain biomedical publications. Clin. Chem. Lab. Med. 40:2002;426-427
58. Lumbreras-Lacarra B., Ramos-Rincon J.M., Hernandez-Aguado I. Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine. Clin. Chem. 50:2004;530-536
59. Kuroki M., Haruno M., Arakawa F., Wakisaka M., Matsuoka Y. Reaction profiles of seven enzyme immunoassay kits for carcinoembryonic antigen (CEA) analyzed with purified preparations of CEA and related normal antigens. Clin. Biochem. 25:1992;29-35
60. Bormer O.P. Major disagreements between immunoassays of carcinoembryonic antigen may be caused by nonspecific cross-reacting antigen 2 (NCA-2). Clin. Chem. 37:1991;1736-1739
61. Orjasaeter H., Staab H.J., Heier H.E., Hornung A., Kjorstad K., Luedin E., et al. Comparison of a CEA-EIA assay based on monoclonal antibody with a CEA-RIA assay with polyclonal antiserum. NHIP Ann. 8:1985;13-26
62. Price T., Beatty B.G., Beatty J.D., McNally A.J. Human anti-murine antibody interference in measurement of carcinoembryonic antigen assessed with a double-antibody enzyme immunoassay. Clin. Chem. 37:1991;51-57
63. Kuroki M., Matsumoto Y., Arakawa F., Haruno M., Murakami M., Kuwa M., et al. Reducing interference from heterophilic antibodies in a two-site immunoassay for carcinoembryonic antigen (CEA) by using a human/mouse chimeric antibody to CEA as the tracer. J. Immunol. Methods. 180:1995;81-91
64. Bakker A.J. Reliability of IFCC method for lactate dehydrogenase in heparin plasma. Clin. Chem. 49:2003;1227
65. Raisky F., Gauthier C., Marchal A., Blum D. Haemolyzed samples: responsibility of short catheters. Ann. Biol. Clin. (Paris). 52:1994;523-527
66. Sharp M.K., Mohammad S.F. Scaling of hemolysis in needles and catheters. Ann. Biomed. Eng. 26:1998;788-797
67. Basuyau J.P., Leroy M., Brunelle P. Determination of tumour markers in serum. Pitfalls and good practice. Clin. Chem. Lab. Med. 39:2001;1227-1233
68. Guder W.G. Preanalytical factors and their influence on analytical quality specifications. Scand. J. Clin. Lab. Invest. 59:1999;545-549
69. Filella X., Cases A., Molina R., Jo J., Bedini J.L., Revert L., et al. Tumor markers in patients with chronic renal failure. Int. J. Biol. Markers. 5:1990;85-88
70. Focan C., Focan-Henrard D., Collette J., Mechkouri M., Levi F., Hrushesky W., et al. Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) in humans. Anticancer Res. 6:1986;1137-1144
71. Touitou Y., Haus E. Biologic rhythms in clinical and laboratory medicine. 1994;Springer-Verlag, Heidelberg, Germany. 730 pp. [2nd printing]
72. Stephens R.W., Nielsen H.J., Christensen I.J., Thorlacius-Ussing O., Sorensen S., Dano K., et al. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J. Natl. Cancer Inst. 91:1999;869-874
73. Wojtukiewicz M.Z., Zacharski L.R., Moritz T.E., Hur K., Edwards R.L., Rickles F.R. Prognostic significance of blood coagulation tests in carcinoma of lung and colon. Blood Coagul. Fibrinolysis. 3:1992;429-437
74. Oosterhuis W.P., Bruns D.E., Watine J., Sandberg S., Horvath A.R. Evidence-based guidelines in laboratory medicine: principles and methods. Clin. Chem. 50(5):2004;. [in press (full text available at: http://www.clinchem.org)]